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ABSTRACT. Prostagiandins, leukotrienes and mono-hydroxy acid products of arachidonic acid were 
measured in mucus of freshly recovered morning stools of a patient with an exacerbation of ulcerative procto- 
colitis. Eicosanoids in ether extracts were separated by high performance liquid chromatography and amounts 
determined by radioimmunoassay. Four hydroxy-eicosatetraenoic acids were detected, of which the most 
important one was identified as 1%hydroxy eicosatetraenoic acid (530 rig/g mucus). Leukotriene B4 was aiso 
present (21 rig/g mucus) and small amounts of immunoreactive leukotriene Cd (< 0.8 rig/g mucus). The pros- 
tagiandins 6-keto-PGFr, and PGE2 and thromboxane B2 were found in amounts of 3.7, 2.0 and 9.2 rig/g 
mucus, respectively. 
INTRODUCTION 
It has been suggested that lipoxygenase products 
play a role in bowel disease and in particular in 
ulcerative colitis (1, 2). In inflammatory bowel 
disease, the synthesis of leukotriene B4 (LTB4) in 
colonic mucosa has been shown to be. enhanced 
compared to normal tissue (3). Using equilibrium 
dialysis of the rectum Lauritsen et al found in- 
creased concentration of prostaglandin E2 and F,, 
and thromboxane B2 in rectal dialysates of patients 
with ulcerative colitis, Crohn’s colitis and 
Clostridium difficile colitis, and substantially in- 
creased levels of leukotriene B4 in patients with 
ulcerative colitis (4, 5). Effects of prednisolone and 
5aminosalicylic acid on these LTI34 levels were in- 
vestigated as well as proven selective 5lipoxygenase 
inhibitors (6). In these in vivo investigations a sig- 
nificant decrease of LTB4 was observed, however 
the clinical efficacy still must be shown in controlled 
trials (7). 
In several animal models of inflammatory bowel 
disease effects of leukotriene synthesis inhibitors is 
investigated. Acute and chronic models have been 
developed in rats (8), rabbits (9) and mice (10). 
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Most studies were focussed on the synthesis or 
measurements of levels of LTB4 and PGE2. Re- 
cently more evidence for the involvement of other 
5-lipoxygenase products, the sulfidopeptide- 
leukotrienes, was found (11, 12). Studies in which 
the metabolism of exogenous arachidonic acid in 
colonic mucosa in inflammatory bowel disease was 
investigated, also showed a 3-5-fold increase of 
other eicosanoids, such as. 12- and 15-HETE and 
HHT (3). It is well known that mono-HETEs act as 
mediators in mucus secretion (13) and have inflam- 
matory effects in skin (14). 
In the present study, lipoxygenase products were 
determined in intestinal mucus from an individual 
with mild ulcerative proctocolitis. Mucus secreted 
with stool was collected from fresh morning stools 
for 4 days, separated and extracted with diethyl- 
ether. The eicosanoids were determined and ident- 
ified by high performance liquid chromatography 
(HPLC) and radioimmunoassay (RIA). High levels 
of another lipoxygenase product, 15-HETE, were 
found in addition to LTB4. 
MATERIALS AND METHODS 
Patient history 
The patient was a 35-year-old man. He started to 
lose blood with his stools when he was 15. After 
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2 years of complaints he was admitted to hospital 
when fiberoptic sigmoidoscopy revealed a friable 
mucosa, frank bleeding and some pseudopolyps. 
The histology was compatible with ulcerative colitis 
and a diagnosis of ulcerative proctocolitis was made. 
A remission was induced with prednisone and sul- 
fasalazine. Several recurrences occurred which 
responded to prednisone and sulfasalazine. Ten 
years thereafter colonoscopy again revealed friable 
mucosa in the rectum and sigmoid with normal 
mucosa in the transverse and descending colon. 
Treatment with prednisone was again instituted 
after a rash developed on sulfasalazine. The steroids 
were gradually tapered off. Since then the patient 
has not been on drug therapy. A fiberoptic sig- 
moidoscopy showed a very mild proctocolitis which 
was confirmed by histology. At the time of the 
study he was feeling well, had no fever and 
produced a stool of normal consistence surrounded 
by mucus, once daily (15). 
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Methods 
Morning stools were collected and mucus separated 
immediately. Extraction was performed with diethyl- 
ether (5 ml per gram mucus). Tritiated prostaglandins 
(PGs), leukotrienes (LTs) and mono-hydroxy- 
eicosatetraenoic acids (HETEs) were added to 
measure recoveries. After centrifugation (5 min, 
2800xg) the supernatant was collected and 
evaporated under nitrogen at 40°C. The extract was 
dissolved in 300 ml of HPLC solvent system and 
filtered over an Acre C3A 0.45 mm filter (Gelman). 
The sample was kept in a plastic micro vial 
(Weichmann, Switzerland). One hundred ml was 
injected into a ChromSep Nucleosil 5Cis column 
(Chrompack, Middelburg, The Netherlands) using 
a 1084B high performance liquid chromatograph of 
Hewlett Packard. The solvent system contained: 
tetrahydrofuran-methanol-o. 1% EDTA in water- 
acetic acid (25:30:45:0.1) adjusted to pH 5.5 
with ammonium hydroxide. The flow rate was 
0.4 ml/min, oven temperature 37°C. Absorption was 
monitored as indicated in the Figure. Fractions of 
1 per min were collected by a LKB Superrac. Twenty- 
five ml portions were used for RIA of LTs and 
HEs. PGs which coelute with LTC4 were measured 
by RIA of 6-keto-prostaglandin Fi, (6-keto-PGFi,), 
thromboxane Bz (TxB2) and prostaglandin E2 
(PGEz), for which purposes 25 ml of the fractions 
4-8 were used. The method was described earlier, 
in detail (16). 
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Fig. RP-HPLC separation of PCs, LTs and HEs in an 
extracted mucus sample of a patient with ulcerative procto 
colitis. A ChromSep Nucleosil 5C,, column (200 x 3.0 mm) 
was used. Mobile phase: tetrahydrofuran-methanol-o. 1% 
EDTA in water-acetic acid (25:30:45:0.1) adjusted to pH 
5.5 with ammonium hydroxide. The flow-rate was 0.9 ml/min, 
oven temperature 37°C. 
Explanation of figures: standards (a) C, D, E and B: t, of 
synthetic LTC,, D,, E, and B4 respectively; standards (0) 
15-H, 12-H and 5-H: 15-HETE, 1ZHETE and 5-HETE, respectively. 
Identification of peaks (as indicated in Results): 1 = front, 
2,3 = tri-HETEs and lipoxins, 4 = LTD,, 5 = LTB, 
(5-(S),12-(R)-dihydroxy-6,8,10,14-eicosatetraenoicacid), 
6 = 5,12- and 8,15-diHETE, 7 = unknown HETE, 
8 = 15HETE, 9 = S- and/or ll-HETE. 
From time 0 absorption was monitored at 280 nm, at time 
13 at 270 nm and at 25 min at 234 nm. Fractions of 1 per min 
were collected from O-18 min for RIA determinations of 
LTC, (O), from O-23 min for immunoassay of LTB, (e), from 
20-60 min for immunoassay of 12-HETE (t@ and from 
20-53 min for the assay of 15-HETE (a). Explanation of 
peaks a-m are given in the Results section. 
In fractions 4-8 PCs were measured (data shown in the Table) 
Chemicals 
Synthetic LTs were generous gifts of Dr. J. Rokach as anti-12-HETE, anti-15-HETE and anti-6-keto- 
(Merck Frosst Labs, Canada), mono-HETEs were PGFi, antibodies. Standards of 6-keto-PGFi,, TxBz 
obtained from Seragen (Boston, MA, USA) as well and PGEz were purchased from Sigma (USA), and 
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anti-T* and anti-PGEz from 1’Institut Pasteur 
(Paris, France). Anti-LTB, was obtained from 
Wellcome Research (UK) and a LTC4 RIA kit from 
Dupont de Nemours (NEN Division, Germany). 
The cross reactivities (> 0.1%) at 50% B/B,, were 
as follows: anti-6kPGFt,: PGFi, 7.8%, 6kPGE 1 
6.8%, PGF2, 2.2%, PGEz 0.6%; anti-TxBz: all 
< 0.1%; anti-PGE2: kPGE2 13.2%, PGEt 10.7%; 
anti-15-HETE: 8,15- and 5,15-diHETE l.O%, 12- 
HETE 0.5%; anti-1ZHETE: 15-HETE 0.3%, 
5-HETE 0.2%; anti-LTB4: all < 0.1%; anti-LTC,: 
11-tr-LTDd 60%, LTD4 55%, LTDd-sulfone lo%, 
LTC4-sulfone and LTE4 9%. All tritiated com- 
pounds were obtained from the Radiochemical 
Centre (Amersham, UK). 
RESULTS 
The Figure shows a separation of lipoxygenase 
products by HPLC (day 2, not corrected for 
recoveries). In this chromatogram the absorption at 
different wave-lengths was monitored (peaks l-9). 
Closed dots represent retention times (tu) of syn- 
thetic leukotrienes and mono-HETEs. The detec- 
tion level was 1 and 5 ng respectively. 
After the front two high peaks were measured, 
indicated by 2 and 3. Immunoassay of these peaks 
revealed very low activities to the LTC4 antibody 
(approx. 0.065 ng max.), as shown in the peaks b 
and c. These compounds could be tri-HETEs or ll- 
trans-LT metabolites. As such derivatives have high 
cross reactivities to the LTC4 antibody, this is un- 
likely. Therefore we assume these peaks to be 
lipoxins (17). Furthermore peaks 4 and d could rep- 
resent either substances of related structure or 
11-trans-LTI&. 
Peak 5 coelutes with LTBl. The corresponding 
peak f contains a fraction with a high immunoreac- 
tivity to LTB4 (approx. 2.7 ng max.). In the fractions 
that were eluted after 20 min, the immunoreactivi- 
ties to 15- and 1ZHETE were determined. Both the 
absorption of peak 7 and the immunoreactivities 
represented in peaks g and k respectively suggest 
that it has the structure of a mono-HETE. 
Peak 8 coeluted with 15-HETE and showed 
immunoreactivity to this compound represented in 
peak 1. The amount was maximal, approximately 
80 ng. There is also cross reactivity with the 12- 
HETE antibody. 
Although no peak in the chromatogram has the 
tn of the IZHETE, two immunoreactive ones were 
found. These contained small amounts of this sub- 
stance (< 0.5 ng). The compound representing 
peak 9 is unknown. Peak j finally indicates the 
presence of very small amounts of 5-HETE. 
Two additional methods were used for the identi- 
fication of peak 8. The absorption spectrum was 
measured and shown to be identical to that of syn- 
thetic 15-HETE. Secondly, the biological activity of 
the peak was measured on human small airway 
smooth muscle (18). It was comparable with the 
small contractile activity of the standard of 15HETE 
and more potent than prostaglandins Fza and E> 
The calculated amounts determined by radio- 
immunoassay were of the same order of magnitude 
as those obtained by measurement of the absorption 
spectrum at the wavelengths indicated. In the Table 
the mean concentrations of eicosanoids in mucus 
obtained from morning stools during 4 days are 
given. Amounts are corrected for recoveries (15) 
and expressed in rig/g mucus. 
Table Concentrations of eicosanoids in mucus of acute 
ulcerative proctocolitis obtained from morning stool during. 4 
days (amounts in rig/g mucus). 
6-keto-PGF,, 3.7 f 1.4 
TXB2 9.2 + 2.5 
PGE, 2.0 f 0.4 
LTBl 21 f 3.0 
LTC, 10.8 
15HETE 530 + 65 
DISCUSSION 
The results indicate that the amounts of LTB4 and 
in particular 15-HETE found in the rectal mucus in 
ulcerative procto colitis are considerably higher than 
the amounts of PGs. Furthermore smaller amounts 
are formed of two other mono-HETEs and a 
di-HETE. Comparatively small, but detectable, 
amounts of sulphidopeptide LTs were measured by 
RIA. Two other non treated patients with ulcerative 
proctocolitis were studied once. Amounts of LTB4 
and 15-HETE were in the same range as those 
shown is this report. Since it is not possible to ob- 
tain mucus from normal individuals other than by 
biopsies the results reported here only support the 
possible important role of mono-hydroxy acids in 
active ulcerative colitis. Measurements of exogen- 
ous 15-HETE, LTBJ and PGEz in controls and pa- 
tients with ulcerative colitis generated from 14C- 
arachidonic acid labelled biopsies confirmed the 
ratios found in the herewith presented results (un- 
published results). 
Recent studies of experimental colitis have estab- 
lished a relationship between LTB4 and LTC4 and 
the severity of the inflammation. Eicosanoid pro- 
duction progressively increased during development 
of inflammation and infiltration of inflammatory 
cells (9). In the model used methylprednisolone was 
not a potent suppressor of LT production (19). In 
Crohn’s disease, enhanced LTB4, C4 and D4 pro- 
duction by colonic mucosa has been described. This 
formation was dose-dependently inhibited by 
sulphasalazine and 5-aminosalicylic acid (11). The 
58 Prostaglandins Leukotrienes and Essential Fatty Acids 
sulfidopeptide LTs Cd, D4 and E4 are known to 
increase mucus production (13)) vascular 
permeability (20) and to contract intestinal smooth 
muscle (21). The chemotactic LTB4 has also been 
shown to increase vascular permeability (22), to 
contract smooth muscle and to increase epithelial 
secretion (23). 
In small bowel mucosa from celiac patients it was 
found that 15HETE formation was increased after 
in vitro challenge with gluten (24). Mono-HETEs 
have been shown to act as mediators of tracheal 
mucus secretion (13, 25)) and have inflammatory 
effects in the skin (14). Additionally it was found 
that 1%HETE inhibits the formation and the chemo- 
tactic response of neutrophils to LTB4, determined 
in synovial fluid in experimental arthritis (26). This 
m&y lead to an increase of cyclooxygenase products. 
In turn misoprostol, a PGEl analogue, can cause an 
inhibition of the initiating event and the amplifi- 
cation of the inflammation caused by LTBJ (27). 
In our study there was a linear relationship be- 
tween the 15-HETE and PG contents, whereas the 
amount of LTB4 was inversely proportional to that 
of the PG (data not shown). 
The implications of our observation, that 15- 
HETE is present in high concentrations in mucus, 
for the treatment of ulcerative colitis, are not clear. 
Though 5-ASA is a rather weak inhibitor of 5- 
lipoxygenase the use of more active and specific 
5-lipoxygenase inhibitors in ulcerative colitis is being 
considered (28). Selective 5-lipoxygenase inhibitors, 
however, could result in increased 15-HETE, 
diHETE and lipoxin production, and may therefore 
prove disappointing anti-inflammatory agents for 
inflammatory bowel disease. 
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